Skip to main content
Cytotechnology logoLink to Cytotechnology
. 2005 Jan;47(1-3):51–57. doi: 10.1007/s10616-005-3764-5

Preparation of Cationic Immunovesicles Containing Cationic Peptide Lipid for Specific Drug Delivery to Target Cells

Takuya Sugahara 1, Shinichi Kawashima 2, Akiko Oda 1, Yoshio Hisaeda 3, Keiichi Kato 2,
PMCID: PMC3449823  PMID: 19003044

Abstract

The cationic vesicle composed of Span80 and cationic peptide lipid (CPL) was prepared. The cytotoxicity of the Span80-CPL cationic vesicle was very low compared with Span80 vesicle. Antibody was able to be immobilized on vesicle surface by mediation of protein A. The antigen targeting ability of the antibody-immobilized vesicle (immunovesicle) derived from antibody was evaluated. Our results suggested that the Span80-CPL immunovesicles specifically associate with target cells by the antibody mediation, and the substance capsulated in immunovesicle was transferred into the target cells. This means that the Span80-CPL immunovesicle is expected to achieve a high local concentration of an encapsulated drug at the target.

Full Text

The Full Text of this article is available as a PDF (313.6 KB).

Glossary

CPL

cationic peptide lipid

FBS

fetal bovine serum

FITC

fluorescein isothiocyanate

IADE

isothiocyanic acid dodecyl ester

PBS

phosphate buffered saline

PI

propidium iodide

Span80

sorbitan monooleate

Tween80

polyoxyethylene (20) sorbitan monooleate

References

  1. Bendas G. Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs. 2001;15:215–224. doi: 10.2165/00063030-200115040-00002. [DOI] [PubMed] [Google Scholar]
  2. Kato K., Sugahara T., Kawashima S., Hayashi Y., Yoshihiro A., Sasaki T., et al. Study of the specific binding between lipid vesicles and human–human hybridoma toward either DDS or gene transfection. In: Bernard A., et al., editors. Animal Cell Technology: Products from Cells, Cells as Products. The Netherlands: Kluwer Academic Publishers; 1999. pp. 433–435. [Google Scholar]
  3. Kato K., Ikeda T., Shinozaki M. Lipid-membrane characteristics of large lipid-vesicles prepared by two-step emulsification technique and enzymatic NAD+-recycling in the vesicle. J. Chem. Eng. Japan. 1993;26:212–216. doi: 10.1252/jcej.26.212. [DOI] [Google Scholar]
  4. Kessner S., Krause A., Rothe U., Bendas G. Investigation of the cellular uptake of E-Selectin-treated immunoliposomes by activated human endothelial cells. Biochim. Biophys. Acta. 2001;1541:177–190. doi: 10.1016/s0005-2736(01)00368-6. [DOI] [PubMed] [Google Scholar]
  5. Maruyama K., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab’ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 1997;413:177–180. doi: 10.1016/S0014-5793(97)00905-8. [DOI] [PubMed] [Google Scholar]
  6. Murakami H., Masui H., Sato G.H., Sueoka N., Chow T.P., Kono-Sueoka T. Growth of hybridoma cells in serum-free medium. Proc. Natl. Acad. Sci. USA. 1982;79:1158–1162. doi: 10.1073/pnas.79.4.1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Murakami H., Hashizume S., Ohashi H., Shinohara K., Yasumoto K., Nomoto K., Omura H. Human–human hybridomas secreting antibodies specific to human lung carcinoma. In Vitro Cell. Dev. Biol. 1985;21:593–596. doi: 10.1007/BF02620891. [DOI] [PubMed] [Google Scholar]
  8. Murakami Y., Naklano A., Ikeda H. Preparation of stable single-compartment vesicles with cationic and zwitterionic amphiphiles involving amino acid residues. J. Org. Chem. 1982;47:2137–2144. doi: 10.1021/jo00132a030. [DOI] [Google Scholar]
  9. Murakami Y., Nakano A., Yoshimatsu A., Uchitomi K., Matsuda Y. Characterization of molecular aggregates of peptide amphiphiles and kinetics of dynamic processes performed by single-walled vesicle. J. Am. Chem. Soc. 1984a;106:3613–3623. doi: 10.1021/ja00324a034. [DOI] [Google Scholar]
  10. Murakami Y., Hisaeda Y., Ohno T. Hydrophobic vitamin B12. III. Incorporation of hydrophobic vitamin B12 derivatives into single-compartment vesicles and their alkylation in various molecular aggregates. Bull. Chem. Soc. Jpn. 1984b;57:2091–2097. [Google Scholar]
  11. Murakami Y., Hisaeda Y., Ohno T. Hydrophobic vitamin B12. Part 9. An artificial holoenzyme composed of hydrophobic vitamin B12 and synthetic bilayer membrane for carbon-skeleton rearrangements. J. Chem. Soc. Perkin Trans. 1991;2:405–416. [Google Scholar]
  12. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 2002;8:1172–1181. [PubMed] [Google Scholar]
  13. Sugahara T., Ohama Y., Fukuda A., Hayashi M., Kawakubo A., Kato K. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles. Cytotechnology. 2001;36:93–99. doi: 10.1023/A:1014057407251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yoshioka T., Sternberg B., Florence A.T. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span85) Int. J. Pharm. 1994;105:1–6. doi: 10.1016/0378-5173(94)90228-3. [DOI] [Google Scholar]

Articles from Cytotechnology are provided here courtesy of Springer Science+Business Media B.V.

RESOURCES